PDPatricia Dubot

Patricia Dubot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patricia Dubot has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Etude du rôle de la glucosylcéramidase dans le mélanome cutané

    by Patricia Dubot

    Le mélanome cutané (MC) est le cancer le plus sévère des cancers de la peau dont l'incidence ne cesse d'augmenter. Malgré des avancées majeures dans la prise en charge du MC avec le développement des thérapies ciblées et de l'immunothérapie, le pronostic des patients atteint de MC reste mauvais. Dans le mélanome cutané, des altérations du métabolisme des sphingolipides, une classe de lipide particulier, ont été montrées par notre équipe et d'autres. Ces altérations pourraient avoir un rôle dans la survenue, la progression et la résistance aux thérapies et s'articulent essentiellement autour d'une diminution de la production du céramide, considéré comme un anti-oncométabolite, et en faveur d'une augmentation de sphingosine-1-phosphate, considéré comme un oncométabolite. La glucosylcéramidase, codée par le gène GBA, est une enzyme lysosomale qui catalyse la dernière étape du catabolisme des sphingolipides transformant le glucosylcéramide (GlcCer) en céramide. L'analyse d'un exome de patients atteints de MC a révélé des mutations faux-sens dans le gène GBA. Le déficit en GCase est connu pour être responsable de la maladie de Gaucher, une maladie de surcharge lysosomale dans laquelle les patients présentent une organomégalie avec ou sans troubles neurologiques. L'origine de ces symptômes serait l'accumulation du GlcCer qui n'est plus dégradé, ainsi que sa forme déacylée, la glucosylsphingosine (GlcSph). De plus, ces patients ont un risque accru de développer des cancers et notamment le mélanome cutané. Le rôle de ces métabolites dans le développement des cancers est évoqué. Parallèlement, les mutations de GBA, à l'état homozygotes mais aussi hétérozygotes, sont un facteur de risque de développer la maladie de Parkinson, une maladie neurodégénérative dans laquelle des agrégats d'alpha-synucléine sont retrouvés dans les neurones. Le déficit en GCase, via l'accumulation en GlcCer et GlcSph, favoriserait l'agrégation d'alpha-synucléine. De façon intéressante, les patients atteints de la maladie de Parkinson présente un risque augmenté de développer un mélanome cutané. Les agrégats d'alpha-synucléine, secondaire au déficit en GCase, pourrait jouer un rôle dans la mélanomagenèse. Les mécanismes qui sous-tendent le lien entre la maladie de Gaucher et le mélanome cutané reste inconnus. Notre projet est de déterminer le rôle de la GCase dans le développement du mélanome cutané. Pour cela, des lignées cellulaires de mélanome humain (A375) ont été utilisées, dans lesquelles l'expression et/ou l'activité de la GCase ont été inhibées par ARN interférence (sh dirigé contre GBA) ou par inhibition pharmacologique (Conduritol B Epoxide) et dans lesquelles la surexpression de la GCase sauvage et mutée a été réalisée par transduction lentivectorale. Ces lignées ont également été traitées par la GlcSph pour l'étude de son implication dans la tumorigenèse. Les propriétés tumorales ont été étudiées comme la prolifération, le cycle cellulaire et la réponse aux thérapies ciblées, ainsi qu'une analyse des sphingolipides. L'expression de l'alpha-synucléine a également été analysée dans ces différents modèles cellulaires. Nous avons montré que l'inhibition de l'expression/activité de la GCase n'a pas modifié les propriétés tumorales comme la prolifération cellulaire et la sensibilité aux thérapies ciblées.

  • Open Access

    Potential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer

    by Patricia Dubot, Leonardo Astudillo, Nicole Therville, Lorry Carrié, Magali Pettazzoni, David Cheillan, Jérôme Stirnemann, Thierry Levade, Nathalie Andrieu-Abadie, Frédérique Sabourdy

    Sphingolipids play a key structural role in cellular membranes and/or act as signaling molecules. Inherited defects of their catabolism lead to lysosomal storage diseases called sphingolipidoses. Although progress has been made toward a better understanding of their pathophysiology, several issues still remain unsolved. In particular, whether lysosphingolipids, the deacylated form of sphingolipids, both of which accumulate in these diseases, are simple biomarkers or play an instrumental role is unclear. In the meanwhile, evidence has been provided for a high risk of developing malignancies in patients affected with Gaucher disease, the most common sphingolipidosis. This article aims at analyzing the potential involvement of lysosphingolipids in cancer. Knowledge about lysosphingolipids in the context of lysosomal storage diseases is summarized. Available data on the nature and prevalence of cancers in patients affected with sphingolipidoses are also reviewed. Then, studies investigating the biological effects of lysosphingolipids toward pro or antitumor pathways are discussed. Finally, original findings exploring the role of glucosylsphingosine in the development of melanoma are presented. While this lysosphingolipid may behave like a protumorigenic agent, further investigations in appropriate models are needed to elucidate the role of these peculiar lipids, not only in sphingolipidoses but also in malignant diseases in general.


  • A diagnosis of progressive myoclonic ataxia guided by blood biomarkers

    by Patricia Dubot, Marie Rafiq, Jonathan Curot, Marion Simonetta-Moreau, Frédérique Sabourdy, Magali Pettazzoni, Roseline Froissart, Thierry Levade, Fabienne Ory-Magne


  • Open Access

    Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses

    by Patricia Dubot, Leonardo Astudillo, Nicole Therville, Frédérique Sabourdy, Jérôme Stirnemann, Thierry Levade, Nathalie Andrieu-Abadie

    The roles of ceramide and its catabolites, i.e., sphingosine and sphingosine 1-phosphate, in the development of malignancies and the response to anticancer regimens have been extensively described. Moreover, an abundant literature points to the effects of glucosylceramide synthase, the mammalian enzyme that converts ceramide to β-glucosylceramide, in protecting tumor cells from chemotherapy. Much less is known about the contribution of β-glucosylceramide and its breakdown products in cancer progression. In this chapter, we first review published and personal clinical observations that report on the increased risk of developing cancers in patients affected with Gaucher disease, an inborn disorder characterized by defective lysosomal degradation of β-glucosylceramide. The previously described mechanistic links between lysosomal β-glucosylceramidase, β-glucosylceramide and/or β-glucosylphingosine, and various hallmarks of cancer are reviewed. We further show that melanoma tumor growth is facilitated in a Gaucher disease mouse model. Finally, the potential roles of the β-glucosylceramidase protein and its lipidic substrates and/or downstream products are discussed.


  • Open Access

    First Report of a Patient with MPS Type VII, Due to Novel Mutations in GUSB, Who Underwent Enzyme Replacement and Then Hematopoietic Stem Cell Transplantation

    by Patricia Dubot, Frédérique Sabourdy, Geneviève Plat, Charlotte Jubert, Claude Cancès, Pierre Broué, Guy Touati, Thierry Levade

    We report the case of a boy who was diagnosed with mucopolysaccharidosis (MPS) VII at two weeks of age. He harbored three missense β-glucuronidase (GUSB) variations in exon 3: two novel, c.422A>C and c.424C>T, inherited from his mother, and the rather common c.526C>T, inherited from his father. Expression of these variations in transfected HEK293T cells demonstrated that the double mutation c.422A>C;424C>T reduces β-glucuronidase enzyme activity. Enzyme replacement therapy (ERT), using UX003 (vestronidase alfa), was started at four months of age, followed by a hematopoietic stem cell allograft transplantation (HSCT) at 13 months of age. ERT was well tolerated and attenuated visceromegaly and skin infiltration. After a severe skin and gut graft-versus-host disease, ERT was stopped six months after HSCT. The last follow-up examination (at the age of four years) revealed a normal psychomotor development, stabilized growth curve, no hepatosplenomegaly, and no other organ involvement. Intriguingly, enzyme activity had normalized in leukocytes but remained low in plasma. This case report illustrates: (i) The need for an early diagnosis of MPS, and (ii) the possible benefit of a very early enzymatic and/or cellular therapy in this rare form of lysosomal storage disease.


  • Inherited monogenic defects of ceramide metabolism: Molecular bases and diagnoses

    by Patricia Dubot, Frédérique Sabourdy, Jitka Rybova, Jeffrey A. Medin, Thierry Levade


  • Open Access

    Pregnancy outcome in Refsum disease: Affected fetuses and children born to an affected mother

    by Patricia Dubot, Léonardo Astudillo, Guy Touati, Julien Baruteau, Pierre Broué, Sandrine Roche, Frédérique Sabourdy, Thierry Levade

    We describe the case of a young woman, from a consanguineous family, affected by adult Refsum disease (ARD, OMIM#266500). ARD is a rare peroxisomal autosomal recessive disease due to deficient alpha‐oxidation of phytanic acid (PA), a branched‐chain fatty acid. The accumulation of PA in organs is thought to be responsible for disease symptoms. The patient presented only bilateral shortening of metatarsals and has been treated with a low‐PA diet. She is homoallelic for the c.135‐2A > G mutation of PHYH, and she married her first cousin carrying the same mutation. She was pregnant seven times and had two homozygous girls. Due to a potential exacerbation of the disease during the third trimester of pregnancy, her weight and plasma PA levels were monitored. No specific events were noticed for the mother during the pregnancies and postpartum periods. This case also raised the question of potential exposure to PA (and its subsequent toxicity) of a homozygous fetus in a homozygous mother. Despite modestly elevated plasma concentrations of PA at birth (<30 μmol/L), the two affected girls did not present any specific sign of ARD and have so far developed normally. As only a few determinations of plasma PA levels in the mother could be performed during pregnancies, showing mild elevations (<350 μmol/L), it remains difficult to conclude as to a possible transplacental crossing of PA.


  • Open Access

    Sweat chloride quantification using capillary electrophoresis

    by Patricia Dubot, Jing Liang, Jacobé Dubs, Yohann Missiak, Cédric Sarazin, François Couderc, Elizabeth Caussé


  • Monogenic neurological disorders of sphingolipid metabolism

    by Frédérique Sabourdy, Leonardo Astudillo, Céline Colacios, Patricia Dubot, Marguerite Mrad, Bruno Ségui, Nathalie Andrieu-Abadie, Thierry Levade